
CNC
Centene Corp
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
26.3352
Open
25.900
VWAP
--
Vol
19.59M
Mkt Cap
12.67B
Low
25.600
Amount
--
EV/EBITDA(TTM)
3.99
Total Shares
533.66M
EV
12.93B
EV/OCF(TTM)
7.47
P/S(TTM)
0.07
Centene Corporation is a healthcare company. The Company provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Its segments include Medicaid, Medicare, Commercial and Other. Specifically, the Medicaid segment includes the Temporary Assistance for Needy Families (TANF) program, Medicaid Expansion programs, the Aged, Blind or Disabled (ABD) program, the Children's Health Insurance Program (CHIP), Long-Term Services and Supports (LTSS), Foster Care, Medicare-Medicaid Plans (MMP), which cover beneficiaries who are dually eligible for Medicaid and Medicare and other state-based programs. The Medicare segment includes Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans and Medicare Prescription Drug Plans. The Commercial segment includes the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
46.63B
+0.02%
2.820
-2.74%
43.95B
+7.71%
-0.905
-213.13%
44.55B
+6.01%
-0.235
-114.51%
Estimates Revision
The market is revising Upward the revenue expectations for Centene Corporation (CNC) for FY2025, with the revenue forecasts being adjusted by 1.71% over the past three months. During the same period, the stock price has changed by -56.91%.
Revenue Estimates for FY2025
Revise Upward

+1.71%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-59.67%
In Past 3 Month
Stock Price
Go Down

-56.91%
In Past 3 Month
15 Analyst Rating

88.21% Upside
Wall Street analysts forecast CNC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNC is 48.54 USD with a low forecast of 30.00 USD and a high forecast of 73.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
8 Hold
1 Sell
Moderate Buy

88.21% Upside
Current: 25.790

Low
30.00
Averages
48.54
High
73.00

88.21% Upside
Current: 25.790

Low
30.00
Averages
48.54
High
73.00
Cantor Fitzgerald
Overweight -> Neutral
downgrade
$38
2025-07-28
New
Reason
Cantor Fitzgerald
Price Target
$38
2025-07-28
New
downgrade
Overweight -> Neutral
Reason
Cantor Fitzgerald downgraded Centene to Neutral from Overweight with a $38 price target.
TD Cowen
Hold
downgrade
$33 -> $30
2025-07-28
New
Reason
TD Cowen
Price Target
$33 -> $30
2025-07-28
New
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Centene to $30 from $33 and keeps a Hold rating on the shares. The firm updated its model after the company uodated its earnings guidance.
Oppenheimer
Oppenheimer
Outperform
to
NULL
downgrade
$51 -> $43
2025-07-28
New
Reason
Oppenheimer
Oppenheimer
Price Target
$51 -> $43
2025-07-28
New
downgrade
Outperform
to
NULL
Reason
Oppenheimer lowered the firm's price target on Centene to $43 from $51 and keeps an Outperform rating on the shares. The firm notes Centene presented a roadmap into 2026 and beyond as it overcomes the operational/regulatory hurdles of Medicaid/Marketplace that the company and its peers are struggling with. The company issued FY2025 EPS guidance of $1.75, vs. prior guidance of over $7.25, with a bridge from prior-levels being driven by -$2.6B from Marketplace; -$2.1B from Medicaid, partially offset by Medicare and cost-management. While the timeline to recovery in each business could be uneven, Centene provides essential services to the healthcare system and should recover margins over time, says Oppenheimer.
UBS
Neutral
downgrade
$45 -> $31
2025-07-28
New
Reason
UBS
Price Target
$45 -> $31
2025-07-28
New
downgrade
Neutral
Reason
UBS lowered the firm's price target on Centene to $31 from $45 and keeps a Neutral rating on the shares.
Truist
Buy
downgrade
$42 -> $35
2025-07-28
New
Reason
Truist
Price Target
$42 -> $35
2025-07-28
New
downgrade
Buy
Reason
Truist lowered the firm's price target on Centene to $35 from $42 but keeps a Buy rating on the shares after its Q2 results. The firm notes that while the environment around cost trends remain difficult and carries near/intermediate term uncertainties, the company's Prescription Drug Plan and Medicare Advantage lines are performing better, the analyst tells investors in a research note.
Cantor Fitzgerald
Overweight -> Neutral
downgrade
$65 -> $38
2025-07-28
New
Reason
Cantor Fitzgerald
Price Target
$65 -> $38
2025-07-28
New
downgrade
Overweight -> Neutral
Reason
As previously reported, Cantor Fitzgerald downgraded Centene to Neutral from Overweight with a price target of $38, down from $65. The firm cites uncertainty in the healthcare exchange and Medicaid markets for the downgrade. Cantor cut estimates on Centene to reflect the company's new guidance. Centene has a heavier mix of earnings in the healthcare exchange market, which faces the greatest level of macro uncertainty, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Centene Corp (CNC.N) is 11.37, compared to its 5-year average forward P/E of 11.77. For a more detailed relative valuation and DCF analysis to assess Centene Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
11.77
Current PE
11.37
Overvalued PE
13.83
Undervalued PE
9.71
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Overvalued
5Y Average EV/EBITDA
9.23
Current EV/EBITDA
13.74
Overvalued EV/EBITDA
10.39
Undervalued EV/EBITDA
8.07
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued
5Y Average PS
0.28
Current PS
0.07
Overvalued PS
0.34
Undervalued PS
0.22
Financials
Annual
Quarterly
FY2025Q2
YoY :
+22.36%
48.74B
Total Revenue
FY2025Q2
YoY :
-132.45%
-402.00M
Operating Profit
FY2025Q2
YoY :
-122.60%
-259.00M
Net Income after Tax
FY2025Q2
YoY :
-123.61%
-0.51
EPS - Diluted
FY2025Q2
YoY :
-20.71%
1.58B
Free Cash Flow
FY2025Q2
YoY :
-47.83%
5.40
Gross Profit Margin - %
FY2025Q2
YoY :
-57.34%
0.61
FCF Margin - %
FY2025Q2
YoY :
-118.40%
-0.53
Net Margin - %
FY2025Q2
YoY :
-24.74%
5.69
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
248.6K
USD
Months
3-6
0
0.0
USD
Months
6-9
7
3.3M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 226.3% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
483.4K
Volume
3
6-9
Months
148.1K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
6
1.6M
Volume
Months
6-9
14
4.2M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
113.0K
USD
8
3-6
Months
16.0K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
16.0K
USD
Months
3-6
5
89.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
8.0K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
248.6K
USD
Months
3-6
0
0.0
USD
Months
6-9
7
3.3M
USD
Months
0-12
0
0.0
USD
Months
CNC News & Events
Events Timeline
2025-07-30 (ET)
2025-07-30
11:19:32
Mixed options sentiment in Centene with shares up 0.92%

2025-07-29 (ET)
2025-07-29
15:37:32
Mixed options sentiment in Centene with shares down 4.37%

2025-07-29
09:05:30
eHealth appoints Derrick Duke as CEO

Sign Up For More Events
Sign Up For More Events
News
9.5
07-28GlobenewswirePinnedCentene Corporation (CNC) Shares Fall ~10% Pre-Market After Reporting Q2 2025 Diluted Loss Per Share, Class Action Lawsuit Over “Inflated Guidance” Pending – Hagens Berman
5.0
07-30PRnewswire'Ohana Health Plan, the Centene Foundation, and Hawai'i Island Community Health Center Unveil New Mobile Clinic to Expand School-Based Healthcare
5.0
07-30NASDAQ.COMWednesday 7/30 Insider Buying Report: CNC, AUB
Sign Up For More News
People Also Watch

HSY
Hershey Co
188.830
USD
+1.40%

MCHP
Microchip Technology Inc
70.290
USD
-0.55%

MPWR
Monolithic Power Systems Inc
730.540
USD
+0.85%

FER
Ferrovial SE
51.970
USD
-1.14%

ANSS
ANSYS Inc
0
USD
-4.92%

VICI
VICI Properties Inc
32.530
USD
-1.03%

AVB
AvalonBay Communities Inc
196.310
USD
-3.35%

RDDT
Reddit Inc
149.330
USD
+3.09%

CAH
Cardinal Health Inc
157.900
USD
+0.32%

WEC
WEC Energy Group Inc
108.360
USD
-0.25%
FAQ

What is Centene Corp (CNC) stock price today?
The current price of CNC is 25.79 USD — it has increased 1.02 % in the last trading day.

What is Centene Corp (CNC)'s business?

What is the price predicton of CNC Stock?

What is Centene Corp (CNC)'s revenue for the last quarter?

What is Centene Corp (CNC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Centene Corp (CNC)'s fundamentals?

How many employees does Centene Corp (CNC). have?
